Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Vaccine Efficacy
94%
Vaccination Policy
52%
Spike
51%
Omicron Coronavirus Variant
49%
Monospecific Antibody
47%
COVID-19
41%
Breakthrough Infection
39%
Adoptive Immunity
31%
Comorbidity
31%
Booster Dose
17%
Neutralizing Antibody
15%
Blocking Antibody
8%
Receptor Blocking
7%
Immune Response
6%
Humoral Immunity
5%
Cytotoxic T-Cell
5%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
60%
COVID-19 Vaccine
47%
Infection
44%
Cellular Immunity
31%
Omicron Coronavirus Variant
18%
Booster Dose
17%
Receptor Blocking
15%
Neutralizing Antibody
15%
Blocking Antibody
12%
Disease
12%
Immune Response
11%
COVID-19
9%
COVID-19 Vaccination
8%
mRNA Vaccine
7%
Study Participant
6%
Charlson Comorbidity Index
6%
Humoral Immunity
6%
Cytotoxic T-Cell
6%
Biochemistry, Genetics and Molecular Biology
SARS Coronavirus
52%
Spike
35%
Comorbidity
31%
Cellular Immunity
31%
Monospecific Antibody
27%
Cohort Study
19%
T Cell
11%
Receptor Blocking
7%
CD4
7%
Cross Protection
6%
CD8
6%
Humoral Immunity
6%
